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Abstract: The clinical aftermath of the reporting of the initial ﬁ  ndings of the Women’s Health 
Initiative (WHI) in 2002 was a profound reduction in the use of hormone therapies by menopausal 
women. This reduction led to a well documented increase in vasomotor symptoms and vaginal 
atrophy among those women who discontinued their hormone regimens. However, another 
adverse impact among these women, as well as many other menopausal women, is the well 
recognized increased likelihood of osteoporosis resulting from the decline in circulating estradiol 
levels associated with natural and surgical menopause. Although the use of non-hormonal drugs 
such as bisphosphonates has been shown to reduce the risk of fracture in women with osteopo-
rosis, bisphosphonates have not been shown to reduce the risk of fracture in non-osteoporotic 
women. Indeed, only oral estrogen (as demonstrated in the WHI studies) has been shown to 
reduce the risk of fracture in osteoporotic and non-osteoporotic women. As non-oral hormone 
therapies have been shown to be as effective in treating vasomotor symptoms and vulvovaginal 
atrophy and to have a different (and perhaps more beneﬁ  cial) physiological effect than oral 
regimens, it behooves us to assess the impact of non-oral hormone regimens on bone mineral 
density and fracture risk. Although there are no clinical trials that primarily assess the impact 
of non-oral regimens on fracture risk in menopausal women, numerous studies are consistent 
in demonstrating the positive impact of non-oral regimens in maintaining and increasing bone 
mineral density among users, even for those women using estrogen doses that are considered 
to be “too low” to have a beneﬁ  cial impact on other menopausal symptoms.
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Introduction
There is almost universal agreement that hormone therapy (HT) effectively treats and 
prevents menopausal symptoms and osteoporosis. These effects have been reported 
in a variety of well-respected observational and randomized clinical trials (RCTs) 
(Raz and Stamm 1993; Writing Group for the Pepi Trial 1996; Greendale et al 1998; 
Notelovitz et al 2000). Controversial issues concerning additional potential risks and 
beneﬁ  ts of HT have received much attention in the medical literature and the lay press, 
particularly as result of the reports from the Women’s Health Initiative (WHI). Indeed, 
the reports from the WHI have cast doubt concerning the safety of all menopausal 
hormone therapies and caused fear and concern among laity as result of the extensive 
press coverage of the ongoing ﬁ  ndings of this trial.
Although the WHI is by far the largest study of the clinical impact of oral hor-
mone therapy in menopausal women, it is profoundly limited in that it has evaluated 
only two oral hormonal regimens and its protocol is mostly limited to the use of 
hormone therapy in an older, but perhaps more importantly, a mostly asymptomatic 
cohort of women who would not have been optimal candidates for hormone therapy 
even during the performance of the study. In particular, the WHI evaluated no non-
oral menopausal hormone therapies; however, regulatory agencies and others have 
unfortunately considered the results of the WHI to be applicable to all regimens until 
data are presented that counter the safety ﬁ  ndings of the WHI. Indeed, this sweeping Clinical Interventions in Aging 2008:3(1) 52
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generalization ignores the considerable evidence, even from 
the WHI, that demonstrates that factors such as age and health 
of the patient (Manson et al 2007) and method of delivery of 
the sex steroids (Scarabin et al 2003) play seminal roles in 
determining the overall safety of the hormone therapy.
With regard to transdermal delivery of estrogen and pro-
gestin for hormone therapy, considerable information exists 
that demonstrates that while the efﬁ  cacy of transdermal sys-
tems for the relief of menopause-related symptoms and condi-
tions is comparable to oral regimens, the physiologic effect 
of these delivery systems is considerably different from that 
observed with oral regimens (Scarabin et al 2003). To this 
end, the use of all estrogen-based therapies have been shown 
to consistently reduce vasomotor symptoms, prevent and 
treat vulvo-vaginal atrophy and prevent bone mineral density 
loss in the vast majority of menopausal women regardless 
of the cause of menopause. This review will assess the role 
of transdermal hormone delivery systems for the prevention 
and treatment of post-menopausal osteoporosis.
Post-menopausal osteoporosis
Osteoporosis is a signiﬁ  cant cause of morbidity and mortality 
in post-menopausal women. At the age of 50, a woman has 
a 40% lifetime chance of an osteoporotic fracture and a 16% 
chance of a hip fracture (Chrischilles et al 1991). Of greatest 
concern is that individuals who suffer from osteoporotic hip 
fractures have up to a 24% risk of death in the year following 
the hip fracture (Johnell and Kanis 2006). These increased 
risks for fracture and their associated morbidity and mortality 
are directly attributable to the loss of bone mineral density 
resulting from the loss of physiologic levels of estrogen 
resulting from surgical or natural menopause.
After menopause, low estrogen levels lead to an imbal-
ance in bone metabolism and a higher rate of bone resorp-
tion. This process leads to a steady decrease in bone mineral 
density (BMD) and bone strength and can result in spinal, hip 
or other bone fractures in the absence of traumatic events. 
While administration of calcium, vitamin D, and exercise 
may temporarily retard bone resorption, they do not prevent 
osteoporosis or fractures.
Osteoporosis therapies
Bisphosphonates and raloxifene have demonstrated fracture 
prevention in women with osteoporosis. However, no data 
show effectiveness in fracture reduction among women 
without osteoporosis, thus causing concern to those women 
looking for fracture reduction before the onset of osteopo-
rosis (Shulman 2004). To this end, the hormone therapy 
arms (combination therapy [HT] and estrogen – alone 
therapy [ET]) of the WHI showed signiﬁ  cant reductions 
in hip fracture in a population not previously diagnosed 
with osteoporosis (Cauley et al 2003). At the end of year 3, 
BMD had increased by 3.7% in the HT group and 0.14% 
in the placebo group (p  0.001). At the end of 5.6 years, 
8.6% (n = 733) of patients receiving HT experienced a frac-
ture, compared with 11% (n = 896) in the placebo group. 
Cumulatively, HT reduced the risk of fracture by 33% in 
a population already at risk for fracture: 44% of the WHI 
subjects were older than 65 years of age. Similar ﬁ  ndings 
were demonstrated in comparing the ET group with the 
placebo group.
Transdermal hormone therapies
Oral estrogen use is strongly associated with maintenance and 
increase in bone mineral density and a reduction in fracture 
risk; however, does transdermal delivery of estrogen, with 
or without a progestin, provide a similar salutary effect on 
bone mineral density and fracture risk? Transdermal estrogen 
therapies have long been shown to be effective in maintain-
ing or increasing bone mineral density among menopausal 
women (Samsioe 2004). However, the study by Ettinger and 
colleagues (2004) showing beneﬁ  cial bone mineral density 
effects of an “ultralow-dose” transdermal estradiol patch 
provides important information to women and clinicians 
considering osteoporotic preventive and therapeutic options. 
Ettinger and colleagues were able to show in this randomized, 
placebo-controlled trial that a transdermal patch delivering 
0.014 mg/d, did not impact vasomotor symptomatology but 
did increase lumbar spine bone mineral density by 2.6% 
versus 0.6 in the placebo group (p  0.001) and did increase 
total hip bone mineral density by 0.4% compared to a 0.8% 
reduction among women in the placebo group (p  0.001). 
These ﬁ  ndings lead to the eventual approval of this method 
(Menostar™) for the prevention of bone mineral density loss 
in menopausal women, although the concomitant ﬁ  nding 
of one woman in the estradiol group (and no women in the 
placebo group) developing endometrial hyperplasia probably 
inﬂ  uenced the FDA to include a somewhat restrictive and 
complicated recommended clinical algorithm for the use of 
this transdermal regimen in the absence of a progestational 
agent. Indeed, studies of low and ultralow-dose regimens 
in all menopausal age groups have shown a consistent and 
signiﬁ  cant increase in bone mineral density and reductions 
in bone turnover markers and no increased risk of endome-
trial hyperplasia or other adverse events compared to oral 
regimens (Richman et al 2006).Clinical Interventions in Aging 2008:3(1) 53
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If an ultralow-dose transdermal therapy is effective in 
maintaining, or even increasing, bone mineral density, what 
about the bone impact of a combination transdermal therapy 
using a higher estrogen dose? Warming and colleagues (2005) 
studied a combination patch with delivering a daily dose of 
45 mcg 17β-estradiol and either 30 or 40 mcg levonorgestrel 
as a 7-day patch over a 2-year study period among osteopenic, 
but not osteoporotic, postmenopausal women. Bone mineral 
density measurements at the lumbar spine, hip and total 
body increased by 8, 6 and 3% (p  0.001) respectively, in 
the hormone groups compared to placebo. All bone markers 
except for urinary Calcium (uCa) were signiﬁ  cantly reduced 
in the hormone groups compared to the placebo group; uCa 
was unchanged. In addition, no signiﬁ  cant dose-related effect 
of levonorgestrel was found and no cases of endometrial 
hyperplasia, uterine cancer or breast cancer were reported 
during the study period. As with other estrogen-alone and 
combination regimens, this study provides conclusive evi-
dence of the beneﬁ  t of transdermal estrogen therapy for the 
prevention of menopause-related osteoporosis.
Unfortunately, there are no meaningful studies directly 
evaluating fracture risk in women using transdermal hor-
mone therapies for menopause management. However, the 
FDA and others have concluded that bone mineral density 
assessment by bone densitometry protocols is an accurate 
surrogate marker for predicting fracture risk in menopausal 
women. Nonetheless, a question concerning hormonal thera-
pies is raised and continues to be an integral part of ongoing 
research; that is, which delivery system, oral or transdermal, 
is better? Again, transdermal delivery systems clearly are 
associated with a different physiological impact than oral 
regimens (Shulman 2004) which may provide a slight 
beneﬁ  t for the use of such regimens given the comparable 
beneﬁ  cial clinical outcomes of oral and non-oral regimens. 
The potential of these pharmacokinetic differences having 
a novel clinical impact on users is best delineated by the 
study by Scarabin and colleagues (2003) who showed that 
women using transdermal hormone therapies had a risk of 
VTE comparable to non-users of hormone therapy and those 
who used oral therapies had an estimated risk of 4.0 compared 
with women using transdermal regimens. Other differences 
found with transdermal use compared to oral use include a 
greater reduction in sympathetic tone (Girdler et al 2004), 
little to no increases in C-reactive protein and an overall 
reduced impact on risk factors for atherosclerotic vascular 
disease (Ho et al 2006).
Given the physiologic differences resulting from oral 
and non-oral hormone regimens, is there any evidence of 
differences comparing oral and non-oral regimens concerning 
bone health? For the most part, clinical impact is considered 
to be a dose-related phenomenon whether it be relief of vaso-
motor symptoms or increases in bone mineral density. Indeed, 
a head-to-head comparison would be almost impossible as 
there would be no good clinical approach to determining the 
relative “sameness” of an oral and transdermal dose of estro-
gen and progestin. Nonetheless, a recent study by Yasui and 
colleagues showed that the effect of transdermal estrogen was 
weaker than that of oral estrogen (conjugated equine estro-
gen) on undercarboxylated osteocalcin (ucOC), a sensitive 
marker of vitamin K status. ucOC is increased after natural 
or surgical menopause; hormone therapy is associated with 
reduced levels of ucOC. The stronger effect of oral hormone 
therapy in this study was believed to be associated with the 
higher triglyceride levels associated with oral therapy, a 
physiologic effect not considered to be generally salutary. 
Regardless, this study gives us an interesting perspective on 
the different physiologic effects of oral and non-oral hormone 
therapies on bone, despite apparently similar beneﬁ  cial clini-
cal outcomes accrued by both delivery systems.
Perhaps the greatest drawback of any hormone therapy 
is compliance and persistence of use. The poor persistence 
with these therapies is not surprising given the preventive 
nature of their use. Ettinger and Pressman (1999) showed that 
2 of 3 women who begin hormone therapy discontinue within 
a year, and continuation with transdermal hormone therapy 
is not as good as with oral regimens. To this end, clinicians 
should provide comprehensive counseling concerning meno-
pause and hormone therapy to women who are considering 
using hormone therapy and empower those women who 
choose to use hormone therapy to select a regimen that is 
most likely to be well incorporated into their lifestyle and, 
if situations change with the use of a particular regimen, be 
ready to change the speciﬁ  c hormone therapy so as to encour-
age its use for as long as the woman remains an appropriate 
candidate for postmenopausal hormone therapy.
Conclusions
The beneﬁ  ts of estrogen therapy for postmenopausal women 
for preventing bone mineral density loss are clear and 
unequivocal. Oral and non-oral therapies have been shown 
to increase bone mineral density in surgically and naturally 
menopausal women. Indeed, a reduction in bone fracture 
has been shown to accrue to women who are osteopenic and 
who use oral estrogen therapy. Despite the lack of fracture 
data for women using transdermal therapies, it is clear that 
these therapies result in a similar salutary impact on bone Clinical Interventions in Aging 2008:3(1) 54
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as observed with oral regimens. Even studies evaluating an 
ultralow, or subtherapeutic dose of transdermal hormone 
therapy have shown important bone effects with regard to 
maintenance and small increases in bone mineral density 
among users.
What appears to be the major issue that currently impacts 
the use of hormone therapy is the deﬁ  nition of “symptomatic 
menopause.” In the United States, Europe and elsewhere, 
many clinicians reserve the use of systemic hormone thera-
pies for only those women with moderate to severe vasomotor 
symptomatology. This practice has arisen out of the initial 
interpretation of the WHI studies and the ongoing mispercep-
tions of hormone use among women. While I do not believe 
that hormone use is for every menopausal woman, or that 
the use of hormone therapy is not associated with clear, and 
in some cases, severe adverse events, the positive impact of 
hormone therapy on bone along with the profound morbidity 
and mortality of osteoporosis must be considered within the 
clinical paradigm of hormone therapy use in menopause. 
Up until now, the beneﬁ  ts of hormone therapy have been, at 
best, a secondary beneﬁ  t accrued by those women with symp-
toms severe enough to warrant consideration of systemic 
therapy. However, the absence of beneﬁ  t of bisphosphonates 
for non-osteoporotic women along with the beneﬁ  ts and 
unique physiologic impact of non-oral regimens, including 
ultralow-dose regimens, should give consideration of the 
use of particular estrogen regimens for the prevention of 
osteoporosis in selected women who are not suffering from 
severe menopause-associated symptoms.
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